New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 27, 2010
14:19 EDTABC, MCK, SNY, HSPRumor: Pharma Distributors move up on speculation of a positive court ruling
Shares of Hospira (HSP), McKesson (MCK) and AmerisourceBergen (ABC) are moving higher on conjecture that a District Court declared Sanofi's patents invalid, clearing the way for generic Taxotere.
News For HSP;MCK;ABC;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
07:33 EDTABCAmerisourceBergen commences tender offer to acquire MWI Veterinary Supply
AmerisourceBergen (ABC) announced that it has commenced a tender offer to purchase all outstanding shares of MWI Veterinary Supply (MWIV) for $190.00 per share, net to the seller in cash, without interest, less any applicable withholding taxes. The tender offer is being made pursuant to the merger agreement entered into by AmerisourceBergen and MWI and announced on January 12. Unless extended, the tender offer will expire at 11:59 p.m., New York City time, on February 23. The completion of the tender offer is subject to the tender of at least a majority of MWI’s outstanding shares of common stock and other customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
07:05 EDTMCKNovaBay signs Avenova distribution agreement with Cardinal Health
Subscribe for More Information
05:14 EDTSNYRegeneron, Sanofi announce BLA for Praluent accepted for priority review by FDA
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the Biologics License Application, or BLA, for Praluent, alirocumab. Under the Prescription Drug User Fee Act, or PDUFA, the goal for a priority review is six months, for a target action date of July 24. Alirocumab is an investigational monoclonal antibody targeting PCSK9 that is intended for the treatment of patients with hypercholesterolemia. The BLA for Praluent contains data from more than 5,000 patients, including 10 Phase 3 ODYSSEY trials. Together with additional ongoing studies including ODYSSEY OUTCOMES, the ODYSSEY clinical trial program will include more than 23,500 patients at more than 2,000 study centers in double-blind, randomized, placebo-and active-controlled trials ranging from 24 weeks to approximately 5 years. Earlier this month, the companies announced that the European Medicines Agency accepted for review the Marketing Authorization Application for Praluent in the European Union. The EMA and FDA have conditionally accepted Praluent as the trade name for alirocumab. The safety and efficacy of alirocumab have not been fully evaluated by any regulatory authority.
January 22, 2015
05:22 EDTSNYGenzyme Cerdelga granted marketing authorization by EC
Subscribe for More Information
January 21, 2015
10:16 EDTSNYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 13, 2015
13:29 EDTMCKMcKesson sees $275M-$325M in synergies from Celesio acquisiton by FY19
Guidance from slides presentation at JPMorgan Healthcare Conference.
13:25 EDTMCKMcKesson backs FY15 EPS view $10.50-$10.90, consensus $10.83
Subscribe for More Information
09:07 EDTHSPHospira says plans to close Clayton, North Carolina facility in 2H15
Subscribe for More Information
08:16 EDTABCAmerisourceBergen price target raised to $100 from $93 at Cowen
Subscribe for More Information
January 12, 2015
10:40 EDTABCMWI Veterinary Supply postpones 2015 annual meeting of stockholders
Subscribe for More Information
09:16 EDTHSPHospira submits Biologics License Application to FDA for Retacrit
Subscribe for More Information
08:57 EDTABCAmerisourceBergen says still 'firmly committed' to special repurchase program
Subscribe for More Information
08:51 EDTABCAmerisourceBergen says will use $500M in cash for MWI purchase
Subscribe for More Information
08:50 EDTABCAmerisourceBergen sees reducing regular shares buybacks in FY15 due to deal
Comment from AmerisourceBergen (ABC) call to discuss acquisition of MWI Veterinary Supply (MWIV).
08:37 EDTSNYShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07:42 EDTABCMWI Veterinary Supply volatility flat into AmerisourceBergen acquiring
MWI Veterinary Supply (MWIV) overall option implied volatility of 30 compares to its 26-week average of 31 according to Track Data, suggesting non-directional price movement into AmerisourceBergen (ABC) acquiring for $190 per share, representing a $2.5B fully diluted equity value.
07:34 EDTABCAmerisourceBergen to acquire MWI Veterinary Supply for $190 per share
Subscribe for More Information
07:33 EDTABCAmerisourceBergen to acquire MWI Veterinary Supply for $190 per share

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use